Patent infringement: JnJ, Momenta Pharma file case against Natco, Mylan Pharma

Hyderabad: Johnson & Johnson's and Momenta Pharmaceuticals have filed a lawsuit against Natco Pharma and its marketing partner Mylan Pharmaceuticals Inc. & others in the US alleging infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate Injection.

Glatiramer Acetate Injection is a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Read also: Lawsuit over Pfizer's disclosures before Chantix recall is dismissed

This lawsuit has been filed in the Pennsylvania Federal Court.

"Natco and its marketing partner, Mylan believe this is a meritless suit for a product that has been in the market for more than 5 years. Mylan and NATCO will strongly defend against this suit," Natco Pharma said in a BSE filing.

Read also: Natco Pharma dragged to Delhi HC over alleged patent violation